Skip to main content
Why a new certification is setting the standard for antibiotic manufacturers
Global Cause
health, wealth and wellbeing of our world
Antimicrobial Resistance
Global Health Resilience
Women and Girls
Wildlife
More
Climate Action
About us
Infectious Diseases
World Food Day
World Oceans Day
Malaria
Circular Economy
Refugees & Migration
Clinical Trials
Vaccines and Immunisation
World Food Day & Sustainable Packaging
Farming
Water
Malaria & NTDs
Neglected Tropical Diseases
HIV AIDS
Maternal health
About us
Body Empowerment
Climate Change
Ending TB
Labour Exploitation
Make a difference
Plant-Based Alternatives
Plastic
Pride
Client survey
Climate Action
About us
Infectious Diseases
World Food Day
World Oceans Day
Malaria
Circular Economy
Refugees & Migration
Clinical Trials
Vaccines and Immunisation
World Food Day & Sustainable Packaging
Farming
Water
Malaria & NTDs
Neglected Tropical Diseases
HIV AIDS
Maternal health
About us
Body Empowerment
Climate Change
Ending TB
Labour Exploitation
Make a difference
Plant-Based Alternatives
Plastic
Pride
Client survey
Sponsored
Biotech investment aims to tackle global AMR crisis
Sponsored
Novel antibiotics are failing to reach patients: here’s why and what needs to change
Sponsored
Antimicrobial resistance threatens treatment progress and the lives of cancer patients
Sponsored
African coordination can turn the tide on AMR
Sponsored
The five steps for a stronger African One Health response to AMR
Sponsored
Revolutionising UTIs diagnosis and treatment in 45 minutes
Sponsored
Phage therapy and the future of global antimicrobial resistance
As antibiotic resistance increases, Armata Pharmaceuticals CEO Dr Deborah Birx shares how Armata is reimagining how we treat bacterial infections, pioneering novel phage therapy for greater clinical impact with minimal harm. Antimicrobial resistance (AMR) is rapidly becoming one of the greatest challenges faced by modern medicine, threatening to render current antibiotic treatments of bacterial infections … Continued
Sponsored
Why we still don’t have enough vaccines for bacterial threats
Sponsored
Patient-derived organoids are de-risking clinical drug development
Sponsored
Patents power innovation against antimicrobial resistance
Sponsored
Afabicin: A new generation of antibiotics to fight AMR
Sponsored
A race against time: antimalarial drug resistance